Totus Medicines today announced its participation at this year’s Future of R&D Week in Boston from October 3-5.
| EMERYVILLE, Calif., Sept. 27, 2023 /PRNewswire/ --Totus Medicines, the drug discovery and development company revolutionizing small molecule drugs to end the era of untreatable disease, today announced its participation at this year’s Future of R&D Week in Boston from October 3-5. Totus Co-founder, CEO, and CSO Neil Dhawan is serving as the Event Chairperson for the first day of the conference, Next-Generation Undruggable and participating throughout the event.
As the Day One Event Chairperson, Neil will be delivering opening and closing remarks, making introductions throughout the day, and moderating the closing panel “2023: The Year of Partnership and Investment Resurgence.” He will also be speaking on the panel ‘Evolution Vs Revolution: How Should the Culture around AI be Managed?’ on October 4. Joining Neil at the conference from Totus are Jimmy Blair, Co-founder and Vice President of Innovation & Partnerships and Hasan Babei, Senior AI/ML Engineer. “This event brings together some of the brightest minds in the pharma and biotech space that are working towards the same mission Totus is – ending the suffering caused by untreatable diseases,” said Dhawan. “It’s an honor to represent my community as event chair and I look forward to engaging in thoughtful discussions about healthcare innovation.” Future of R&D Week consists of three events showcasing innovation in the biotech and pharma space, Next Generation Undruggable, AI in Pharma: Discovery and AI in Pharma: Clinical Development. For more information on Next-Generation Undruggable and Future of R&D Week, visit https://www.nextgenerationundruggable.com/. About Totus Medicines For more information, please visit totusmedicines.com and follow Totus on LinkedIn and Twitter. MEDIA CONTACT
SOURCE Totus Medicines |
View original content to download multimedia:
